University of Michigan Kellogg Eye Center
Welcome,         Profile    Billing    Logout  
 14 Trials 
30 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moroi, Sayoko E
NCT04412096: Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Recruiting
4
100
US
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Ohio State University, University of Nebraska, National Eye Institute (NEI), Mayo Clinic
Glaucoma, OHT - Ocular Hypertension
05/25
08/25
Tanna, Angelo P
COAST, NCT04967989: Clarifying the Optimal Application of SLT Therapy Trial

Recruiting
3
640
Europe, Canada, US
Low Energy SLT, Standard Energy SLT
West Virginia University, University of Pittsburgh
Glaucoma and Ocular Hypertension
06/27
08/27
NCT05790408: Anterior-segment OCT (AS-OCT) and Intraoperative OCT (iOCT) for Trans- Conjunctival Needle Revision (TCNR)

Terminated
N/A
10
US
Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)
Northwestern University
Glaucoma, Glaucoma Following Surgery
01/22
01/22
Jayasundera, K Thiran
NCT06651736: Optimizing Low Vision Rehabilitation in Emotionally Distressed Patients with Inherited Retinal Diseases

Not yet recruiting
N/A
180
US
Low Vision Rehabilitation (LVR), Emotion Regulation Therapy (ERT)
University of Michigan, National Eye Institute (NEI)
Inherited Retinal Diseases
11/28
11/28
Dorshow, Richard B
NCT05425719: Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

Completed
3
249
US, RoW
MB-102, Relmapirazin, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
MediBeacon
Chronic Kidney Disease
02/23
02/23
NCT04008121: Feasibility and Safety of MB-102 in Ocular Angiography As Compared to Fluorescein Sodium

Not yet recruiting
1
10
US
Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
MediBeacon
Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
06/25
06/25
Paulus, Yannis
NCT04008121: Feasibility and Safety of MB-102 in Ocular Angiography As Compared to Fluorescein Sodium

Not yet recruiting
1
10
US
Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
MediBeacon
Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
06/25
06/25
NCT06178978: Device for Age-related Macular Degeneration (AMD)

Completed
N/A
31
US
KalEYEdoscope
University of Michigan
Age-Related Macular Degeneration
03/22
03/22
NCT03076697: Smartphone Screening for Eye Diseases

Enrolling by invitation
N/A
550
NA
Fundus photography
University of Michigan, Washington University School of Medicine, University of California, Berkeley
Diabetes Mellitus, Glaucoma, Age Related Macular Degeneration, ROP, Diabetic Retinopathy, Retinal Disease
06/26
08/28
Wood, Sarah
TAKE Steps, NCT05215262: Motivational Interviewing to Prevent STIs

Completed
N/A
114
US
Treat Act Know Engage (T.A.K.E.) Steps, Standard or Care
Children's Hospital of Philadelphia, National Institute of Mental Health (NIMH)
Self Efficacy, HIV Prevention, STI Prevention
06/24
06/24
S2P, NCT06003192: Screen to Prevent: Using Digital Health to Improve HIV Screening and Prevention

Recruiting
N/A
63000
US
Universal Opt-out HIV Screening
Children's Hospital Medical Center, Cincinnati, University of Utah
HIV Infections
04/27
07/27
Hussain, Munira
BRIDGET, NCT05323955: Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib

Recruiting
2
48
US
Trastuzumab, Herceptin, Trastuzumab Emtansine (T-DM1), Pertuzumab, Perjeta, Tucatinib, Tukysa
Carey Anders, M.D., Pfizer
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
10/26
10/27
NCT03011554: Telescope Exchange Study

Recruiting
N/A
75
US
Implantable Miniature Telescope (IMT)
VisionCare, Inc.
Age-related Macular Degeneration
12/19
12/22
Jayasundera, Thiran K
Platypus, NCT05902962: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Recruiting
1
20
US
VP-001
PYC Therapeutics
Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
05/24
05/24
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
NCT03349242: Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

Completed
N/A
140
Europe, Canada, US
MeiraGTx UK II Ltd, Janssen, LP
Retinitis Pigmentosa
04/24
04/24
NCT05573984: Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

Recruiting
N/A
50
US, RoW
PYC Therapeutics
Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive
12/26
04/27
Gordon, Callie
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
NCT04120883: Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

Terminated
1/2
8
US
Hydroxychloroquine lower dose, plaquenil, Hydroxychloroquine higher dose
University of Michigan, Cures Within Reach
Retinitis Pigmentosa
08/24
08/24
Drada, Adriana
liMeliGhT, NCT06388200: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Recruiting
3
150
US
Sub-Retinal Administration of OCU400-301
Ocugen
Retinitis Pigmentosa
06/25
10/26
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
PRODYGY, NCT05748873: Promising ROd-cone DYstrophy Gene TherapY

Recruiting
1/2
33
Europe, US
SPVN06
SparingVision
Retinitis Pigmentosa
03/25
03/29
Platypus, NCT05902962: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Recruiting
1
20
US
VP-001
PYC Therapeutics
Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
05/24
05/24
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Rao, Rajesh C
NCT04627428: Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Recruiting
1/2
18
US
RPESC-RPE-4W
Luxa Biotechnology, LLC, National Institutes of Health (NIH), National Eye Institute (NEI), Regenerative Research Foundation
Dry Age-related Macular Degeneration
05/25
05/25
Soto, Courtney
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
Platypus, NCT05902962: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Recruiting
1
20
US
VP-001
PYC Therapeutics
Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
05/24
05/24
NCT05573984: Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

Recruiting
N/A
50
US, RoW
PYC Therapeutics
Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive
12/26
04/27
Bicket, Amanda
COAST, NCT04967989: Clarifying the Optimal Application of SLT Therapy Trial

Recruiting
3
640
Europe, Canada, US
Low Energy SLT, Standard Energy SLT
West Virginia University, University of Pittsburgh
Glaucoma and Ocular Hypertension
06/27
08/27
Rudberg, Lindsay
COAST, NCT04967989: Clarifying the Optimal Application of SLT Therapy Trial

Recruiting
3
640
Europe, Canada, US
Low Energy SLT, Standard Energy SLT
West Virginia University, University of Pittsburgh
Glaucoma and Ocular Hypertension
06/27
08/27

Download Options